For example, in ALL or AML, JAK2 inhibitors such as ruxolitinib can help reduce leukemia cell resistance to chemotherapy by disrupting the aberrant signaling that sustains leukemia cell survival. This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.